Veru is an oncology biopharmaceutical company with a principal focus on developing novel medicines for the management of breast and prostate cancers. The Company’s late-stage breast cancer development portfolio comprises enobosarm, a selective androgen receptor targeting agonist, and sabizabulin, a cytoskeleton disruptor.
Information Internet project PharmProm.Net dedicated to the pharmaceutical industry in the world. It contains a contact base of organizations, enterprises, companies associated with the pharmaceutical market. The editorial staff of the PharmProm.Net portal offers cooperation in the field of information promotion and advertising in the pharmaceutical market.